glp-1 drug market competition 2025 Receptor Agonist Size, Share, Growth, 2034 GLP-1 Receptor Agonist Market Size

Lancet (1999) 353(9167):18659

Human relevance of pharmaceutical drug-induced thyroid tumors in rats, labeling implications, and carcinogenicity study requirements

You cannot receive both the 340B ceiling price AND the MFP you get whichever is lower 3

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which has shown promise in treating obesity

For comparison, at a peak of GLP-1 dispensing in early 2023, young women (18-25 years old) were given 45,000 doses compared to less than 15,000 doses to young men (18-25 years old)

Learn more Healthcare analytics MedInsight Adopt the healthcare industrys leading platform for data warehousing and healthcare analytics